Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BOBBY TULLOS

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1841554250
CMS profile
899750
Location
GULFPORT, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$65,599.67

239 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BOBBY TULLOS

NPI 1841554250 · CMS profile ID 899750

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

GULFPORT, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841554250?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BOBBY TULLOS, NPI 1841554250, CMS profile ID 899750. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841554250?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BOBBY TULLOS, NPI 1841554250, CMS profile ID 899750. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841554250?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BOBBY TULLOS, NPI 1841554250, CMS profile ID 899750, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 239 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1841554250?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

239 matching records · $65,599.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 239 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 239.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $16.5707/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002671107 CMS
Mylan Specialty L.P. $19.6207/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039109507 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.9607/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996884951 CMS
Regeneron Healthcare Solutions, Inc. $20.7107/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999502789 CMS
GlaxoSmithKline, LLC. $45.8507/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002641495 CMS
GlaxoSmithKline, LLC. $45.8507/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002645905 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.8407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996884955 CMS
GlaxoSmithKline, LLC. $3,900.0007/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002646019 CMS
GlaxoSmithKline, LLC. $10.7207/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002668763 CMS
Amgen Inc. $30.6907/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019836091 CMS
Mallinckrodt Hospital Products Inc. $15.4207/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042917945 CMS
AstraZeneca Pharmaceuticals LP $19.1407/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011371325 CMS
GlaxoSmithKline, LLC. $10.7206/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002643521 CMS
Philips Electronics North America Corporation $20.8006/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024016169 CMS
Mylan Specialty L.P. $13.3006/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039095631 CMS
Regeneron Healthcare Solutions, Inc. $25.4306/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999502781 CMS
GlaxoSmithKline, LLC. $3,900.0006/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002641665 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.5006/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000669661 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.8006/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055644563 CMS
Actelion Pharmaceuticals US, Inc. $24.0706/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988767721 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.4606/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996884957 CMS
GlaxoSmithKline, LLC. $1,300.0006/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002641575 CMS
GlaxoSmithKline, LLC. $18.1906/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002668857 CMS
Regeneron Healthcare Solutions, Inc. $37.4906/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999502773 CMS
Bayer Healthcare Pharmaceuticals Inc. $45.0006/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000682729 CMS
GlaxoSmithKline, LLC. $1.2106/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002645873 CMS
Gilead Sciences, Inc. $23.5606/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025689125 CMS
Noah Medical Corporation $153.4406/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057645491 CMS
Merck Sharp & Dohme LLC $26.3306/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048760549 CMS
United Therapeutics Corporation $19.3305/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050952669 CMS
Mylan Specialty L.P. $125.0005/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039131015 CMS
Mylan Specialty L.P. $935.0005/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039131727 CMS
Mylan Specialty L.P. $3,671.2505/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039132211 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.5905/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055644557 CMS
AstraZeneca Pharmaceuticals LP $14.3705/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011739479 CMS
GlaxoSmithKline, LLC. $5.1705/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002641567 CMS
Mylan Specialty L.P. $19.9505/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039087229 CMS
Mallinckrodt Hospital Products Inc. $28.4805/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042917937 CMS
Olympus America Inc. $2.6605/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035394267 CMS
Electromed, Inc. $13.4205/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 977402837 CMS
United Therapeutics Corporation $20.2005/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050953549 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.6005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996884961 CMS
Regeneron Healthcare Solutions, Inc. $30.4805/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999502765 CMS
Grifols USA, LLC $18.4705/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011813901 CMS
Janssen Pharmaceuticals, Inc $17.6305/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988616015 CMS
Philips Electronics North America Corporation $15.6505/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024016165 CMS
GlaxoSmithKline, LLC. $14.5205/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002646040 CMS
GlaxoSmithKline, LLC. $21.3405/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002668913 CMS
GlaxoSmithKline, LLC. $17.5605/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002641489 CMS
Grifols USA, LLC $24.4905/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011813937 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $20,108.83 138
PY2020 $17,462.30 44
PY2021 $34,404.80 114
PY2022 $49,081.60 196
PY2023 $65,599.67 239
PY2024 $34,913.25 204
PY2025 $54,885.82 229

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $71,198.24 86
PY2024 Principal investigator $13,278.99 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,838.60 12/05/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220793361
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 12/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750110
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 12/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811964
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 12/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811966
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 11/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750116
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 11/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811960
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 11/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811962
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,257.20 10/07/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220793359
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 10/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750114
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 10/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811956
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 10/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811958
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 09/24/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750100
Principal investigator 1 Boehringer Ingelheim International GmbH $61.07 09/24/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750102
Principal investigator 1 Boehringer Ingelheim International GmbH $20.73 09/24/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750104
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 09/24/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750106
Principal investigator 1 Boehringer Ingelheim International GmbH $7.50 09/24/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750108
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 09/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750112
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 09/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811952
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 09/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811954
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $184.00 08/27/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811942
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $85.00 08/27/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811944
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $85.00 08/27/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811946
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 08/26/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750092
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 08/26/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750094
Principal investigator 1 Boehringer Ingelheim International GmbH $3.36 08/26/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750096
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 08/26/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750098
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,112.00 08/15/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220793357
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 08/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750064
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 08/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750090
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 08/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811948
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 08/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811950
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 07/28/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220793373
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,530.60 07/11/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220793355
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,567.00 07/09/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220793371
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 07/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750062
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 07/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811938
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 07/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811940
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $250.00 06/26/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220793353
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750080
Principal investigator 1 Boehringer Ingelheim International GmbH $61.07 06/24/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750082
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 06/24/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750084
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 06/24/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750086
Principal investigator 1 Boehringer Ingelheim International GmbH $6.50 06/24/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750088
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,207.00 06/18/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220793369
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 06/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750052
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 06/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811934
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 06/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811936
Principal investigator 1 Boehringer Ingelheim International GmbH $4.34 05/27/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750058
Principal investigator 1 Boehringer Ingelheim International GmbH $4.34 05/27/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750060
Principal investigator 1 Boehringer Ingelheim International GmbH $2.10 05/27/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750078
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,228.80 05/14/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220793351
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,831.00 05/13/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220793367
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 05/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750050
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 05/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811930
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 05/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811932
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 04/23/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750054
Principal investigator 1 Boehringer Ingelheim International GmbH $13.14 04/23/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750056
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 04/23/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750066
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 04/23/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750068
Principal investigator 1 Boehringer Ingelheim International GmbH $305.35 04/23/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750070
Principal investigator 1 Boehringer Ingelheim International GmbH $103.65 04/23/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750072
Principal investigator 1 Boehringer Ingelheim International GmbH $11.76 04/23/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750074
Principal investigator 1 Boehringer Ingelheim International GmbH $46.50 04/23/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220750076
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,471.00 04/04/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220793363
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 04/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750044
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 04/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750046
Principal investigator 1 Boehringer Ingelheim International GmbH $45.71 04/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750048
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 04/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811926
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 04/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811928
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 03/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750028
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 03/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811922
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 03/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811924
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 02/25/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750038
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 02/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750026
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,000.00 02/01/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220793349
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 02/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811918
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 02/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811920
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 01/27/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750030
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 01/27/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750032
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 01/27/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750034
Principal investigator 1 Boehringer Ingelheim International GmbH $65.70 01/27/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750036
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,000.00 01/21/2025 Covered Recipient Teaching Hospital
Memorial Hospital At Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220793365
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 01/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750040
Principal investigator 1 Boehringer Ingelheim International GmbH $2,029.50 01/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220750042
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42.00 01/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811914
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $232.00 01/01/2025 Non-covered Recipient Entity
Memorial Hospital Gulfport
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220811916